Nuevolution’s BET-BD1 selective inhibitor and candidate compound, NUE20798, shows positive effect on disease scoring and biomarker levels in an atopic dermatitis (eczema) mouse model
Stockholm, 9 May 2019. Nuevolution AB (publ) (NUE.ST) today announced completion of positive data for NUE20798 from an atopic dermatitis (eczema) mouse model showing reduction of both disease - and clinical biomarker levels. No negative effect was observed on the blood platelet count (so-called thrombocytopenia) when using Nuevolution’s selective bromodomain inhibitor NUE20798. Nuevolution has developed potent and selective compounds, with a benign safety profile targeting the first bromodomain of the BET family of proteins and recently nominated NUE20798 as its development candidate.